Metabolic Solutions Development Company (MSDC) is a company that discovers and develops molecular targets and therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. It offers MSDC-0160 and MSDC-0602, therapeutic drugs, which selectively modulate mitochondrial control of important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes.